Pushkal P. Garg's most recent trade in Alnylam Pharmaceuticals Inc was a trade of 5,445 Common Stock done at an average price of $300 . Disclosure was reported to the exchange on March 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 300.00 per share. | 21 Mar 2025 | 5,445 | 20,221 (0%) | 0% | 300 | 1,633,500 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.22 per share. | 21 Mar 2025 | 5,445 | 25,666 (0%) | 0% | 42.2 | 229,888 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2025 | 5,445 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 285.00 per share. | 21 Mar 2025 | 4,321 | 20,221 (0%) | 0% | 285 | 1,231,485 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 14,137 | 27,099 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 7,819 | 7,819 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 243.13 per share. | 03 Mar 2025 | 583 | 25,740 (0%) | 0% | 243.1 | 141,745 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 240.92 per share. | 03 Mar 2025 | 343 | 24,860 (0%) | 0% | 240.9 | 82,636 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 244.43 per share. | 03 Mar 2025 | 273 | 25,467 (0%) | 0% | 244.4 | 66,729 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 243.36 per share. | 03 Mar 2025 | 235 | 26,651 (0%) | 0% | 243.4 | 57,190 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 242.37 per share. | 03 Mar 2025 | 213 | 26,886 (0%) | 0% | 242.4 | 51,625 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 241.60 per share. | 03 Mar 2025 | 198 | 24,662 (0%) | 0% | 241.6 | 47,837 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 244.41 per share. | 03 Mar 2025 | 158 | 26,493 (0%) | 0% | 244.4 | 38,617 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 239.25 per share. | 03 Mar 2025 | 147 | 25,203 (0%) | 0% | 239.3 | 35,170 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 242.70 per share. | 03 Mar 2025 | 120 | 24,542 (0%) | 0% | 242.7 | 29,124 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 245.53 per share. | 03 Mar 2025 | 117 | 25,350 (0%) | 0% | 245.5 | 28,727 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 245.26 per share. | 03 Mar 2025 | 116 | 26,377 (0%) | 0% | 245.3 | 28,450 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 246.19 per share. | 03 Mar 2025 | 48 | 26,329 (0%) | 0% | 246.2 | 11,817 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 247.40 per share. | 03 Mar 2025 | 5 | 26,324 (0%) | 0% | 247.4 | 1,237 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 248.00 per share. | 03 Mar 2025 | 1 | 26,323 (0%) | 0% | 248 | 248 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 1,908 | 1,908 | - | - | Restricted Stock Units | |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 1,908 | 13,897 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 242.44 per share. | 27 Feb 2025 | 352 | 13,173 (0%) | 0% | 242.4 | 85,339 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 241.51 per share. | 27 Feb 2025 | 149 | 13,525 (0%) | 0% | 241.5 | 35,985 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 243.23 per share. | 27 Feb 2025 | 142 | 13,031 (0%) | 0% | 243.2 | 34,539 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 240.32 per share. | 27 Feb 2025 | 91 | 13,674 (0%) | 0% | 240.3 | 21,869 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 244.12 per share. | 27 Feb 2025 | 69 | 12,962 (0%) | 0% | 244.1 | 16,844 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 236.51 per share. | 27 Feb 2025 | 51 | 13,846 (0%) | 0% | 236.5 | 12,062 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 239.17 per share. | 27 Feb 2025 | 41 | 13,765 (0%) | 0% | 239.2 | 9,806 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 238.32 per share. | 27 Feb 2025 | 40 | 13,806 (0%) | 0% | 238.3 | 9,533 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 3,109 | 15,098 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 250.11 per share. | 13 Feb 2025 | 862 | 12,675 (0%) | 0% | 250.1 | 215,595 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 253.37 per share. | 13 Feb 2025 | 386 | 14,363 (0%) | 0% | 253.4 | 97,801 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 252.50 per share. | 13 Feb 2025 | 349 | 14,749 (0%) | 0% | 252.5 | 88,123 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 250.73 per share. | 13 Feb 2025 | 306 | 12,369 (0%) | 0% | 250.7 | 76,723 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 254.35 per share. | 13 Feb 2025 | 258 | 14,105 (0%) | 0% | 254.3 | 65,622 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 256.29 per share. | 13 Feb 2025 | 126 | 13,869 (0%) | 0% | 256.3 | 32,293 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 251.60 per share. | 13 Feb 2025 | 110 | 12,259 (0%) | 0% | 251.6 | 27,676 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 255.56 per share. | 13 Feb 2025 | 110 | 13,995 (0%) | 0% | 255.6 | 28,112 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 257.99 per share. | 13 Feb 2025 | 107 | 12,069 (0%) | 0% | 258.0 | 27,605 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 256.05 per share. | 13 Feb 2025 | 83 | 12,176 (0%) | 0% | 256.0 | 21,252 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 259.10 per share. | 13 Feb 2025 | 80 | 11,989 (0%) | 0% | 259.1 | 20,728 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 258.06 per share. | 13 Feb 2025 | 77 | 13,732 (0%) | 0% | 258.1 | 19,871 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 257.52 per share. | 13 Feb 2025 | 60 | 13,809 (0%) | 0% | 257.5 | 15,451 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 261.45 per share. | 13 Feb 2025 | 60 | 13,596 (0%) | 0% | 261.5 | 15,687 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 260.57 per share. | 13 Feb 2025 | 49 | 13,656 (0%) | 0% | 260.6 | 12,768 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 264.88 per share. | 13 Feb 2025 | 32 | 13,537 (0%) | 0% | 264.9 | 8,476 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 263.33 per share. | 13 Feb 2025 | 27 | 13,569 (0%) | 0% | 263.3 | 7,110 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 259.70 per share. | 13 Feb 2025 | 27 | 13,705 (0%) | 0% | 259.7 | 7,012 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 285.00 per share. | 27 Jan 2025 | 52,592 | 11,989 (0%) | 0% | 285 | 14,988,720 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 25,000 | 0 | - | - | Performance Stock Option 2015 (right to buy) | |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.95 per share. | 27 Jan 2025 | 25,000 | 64,581 (0%) | 0% | 89.0 | 2,223,750 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 23,876 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.95 per share. | 27 Jan 2025 | 23,876 | 39,581 (0%) | 0% | 88.9 | 2,123,770 | Common Stock |
| Alnylam Pharmaceuticals Inc | P. Pushkal Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 251.68 per share. | 12 Dec 2024 | 778 | 15,946 (0%) | 0% | 251.7 | 195,807 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg P. | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 250.08 per share. | 12 Dec 2024 | 426 | 16,724 (0%) | 0% | 250.1 | 106,534 | Common Stock |
| Alnylam Pharmaceuticals Inc | P. Pushkal Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 248.99 per share. | 12 Dec 2024 | 186 | 17,150 (0%) | 0% | 249.0 | 46,312 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg P. | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 254.37 per share. | 12 Dec 2024 | 140 | 15,706 (0%) | 0% | 254.4 | 35,612 | Common Stock |
| Alnylam Pharmaceuticals Inc | Garg P. Pushkal | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 247.48 per share. | 12 Dec 2024 | 121 | 17,336 (0%) | 0% | 247.5 | 29,945 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg P. | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 252.94 per share. | 12 Dec 2024 | 100 | 15,846 (0%) | 0% | 252.9 | 25,294 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg P. | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 256.00 per share. | 12 Dec 2024 | 1 | 15,705 (0%) | 0% | 256 | 256 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg P. | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Nov 2024 | 3,434 | 19,139 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Pushkal Garg P. | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 251.42 per share. | 25 Nov 2024 | 945 | 17,554 (0%) | 0% | 251.4 | 237,592 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 250.68 per share. | 25 Nov 2024 | 364 | 18,499 (0%) | 0% | 250.7 | 91,248 | Common Stock |
| Alnylam Pharmaceuticals Inc | Garg P. Pushkal | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 249.60 per share. | 25 Nov 2024 | 246 | 18,863 (0%) | 0% | 249.6 | 61,402 | Common Stock |
| Alnylam Pharmaceuticals Inc | P. Pushkal Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 252.27 per share. | 25 Nov 2024 | 97 | 17,457 (0%) | 0% | 252.3 | 24,470 | Common Stock |
| Alnylam Pharmaceuticals Inc | P. Pushkal Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 247.77 per share. | 25 Nov 2024 | 30 | 19,109 (0%) | 0% | 247.8 | 7,433 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2024 | 96 | 15,705 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 4,295 | 17,712 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 229.93 per share. | 24 Jun 2024 | 398 | 16,633 (0%) | 0% | 229.9 | 91,512 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 229.06 per share. | 24 Jun 2024 | 348 | 17,031 (0%) | 0% | 229.1 | 79,713 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 232.54 per share. | 24 Jun 2024 | 283 | 16,221 (0%) | 0% | 232.5 | 65,809 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 234.66 per share. | 24 Jun 2024 | 242 | 15,828 (0%) | 0% | 234.7 | 56,788 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 235.19 per share. | 24 Jun 2024 | 219 | 15,609 (0%) | 0% | 235.2 | 51,507 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 228.30 per share. | 24 Jun 2024 | 169 | 17,379 (0%) | 0% | 228.3 | 38,583 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 233.53 per share. | 24 Jun 2024 | 151 | 16,070 (0%) | 0% | 233.5 | 35,263 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 231.59 per share. | 24 Jun 2024 | 129 | 16,504 (0%) | 0% | 231.6 | 29,875 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 221.71 per share. | 24 Jun 2024 | 78 | 17,634 (0%) | 0% | 221.7 | 17,293 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 226.82 per share. | 24 Jun 2024 | 45 | 17,548 (0%) | 0% | 226.8 | 10,207 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 225.54 per share. | 24 Jun 2024 | 24 | 17,593 (0%) | 0% | 225.5 | 5,413 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 224.18 per share. | 24 Jun 2024 | 17 | 17,617 (0%) | 0% | 224.2 | 3,811 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg P. | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 9,279 | 9,279 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Pushkal Garg P. | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 4,751 | 13,417 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Garg Pushkal P. | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 1,908 | 3,816 | - | - | Restricted Stock Units | |
| Alnylam Pharmaceuticals Inc | Garg Pushkal P. | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 1,908 | 9,240 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Garg Pushkal P. | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 154.54 per share. | 27 Feb 2024 | 247 | 8,993 (0%) | 0% | 154.5 | 38,171 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg P. | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 155.45 per share. | 27 Feb 2024 | 194 | 8,799 (0%) | 0% | 155.4 | 30,157 | Common Stock |
| Alnylam Pharmaceuticals Inc | Garg Pushkal P. | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 156.38 per share. | 27 Feb 2024 | 115 | 8,684 (0%) | 0% | 156.4 | 17,984 | Common Stock |
| Alnylam Pharmaceuticals Inc | Garg Pushkal P. | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 157.29 per share. | 27 Feb 2024 | 17 | 8,667 (0%) | 0% | 157.3 | 2,674 | Common Stock |
| Alnylam Pharmaceuticals Inc | Garg Pushkal P. | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 158.00 per share. | 27 Feb 2024 | 1 | 8,666 (0%) | 0% | 158 | 158 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg P. | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 4,295 | 8,640 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Garg Pushkal P. | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 148.24 per share. | 15 Feb 2024 | 672 | 7,488 (0%) | 0% | 148.2 | 99,617 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg P. | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 147.50 per share. | 15 Feb 2024 | 480 | 8,160 (0%) | 0% | 147.5 | 70,800 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg P. | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 149.03 per share. | 15 Feb 2024 | 156 | 7,332 (0%) | 0% | 149.0 | 23,249 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 4,518 | 8,863 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Pushkal Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 183.58 per share. | 03 Aug 2023 | 3,112 | 5,399 (0%) | 0% | 183.6 | 571,301 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 3,109 | 11,972 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Pushkal Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 185.54 per share. | 03 Aug 2023 | 1,593 | 9,721 (0%) | 0% | 185.5 | 295,565 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 186.39 per share. | 03 Aug 2023 | 945 | 8,776 (0%) | 0% | 186.4 | 176,139 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 184.65 per share. | 03 Aug 2023 | 814 | 4,585 (0%) | 0% | 184.6 | 150,305 | Common Stock |
| Alnylam Pharmaceuticals Inc | Pushkal Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 184.70 per share. | 03 Aug 2023 | 658 | 11,314 (0%) | 0% | 184.7 | 121,533 | Common Stock |